- Home
- GALT vs SNTI Comparison
GALT vs SNTI Comparison
Compare GALT & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- SNTI
- Stock Information
- Founded
- GALT 2000
- SNTI 2016
- Country
- GALT United States
- SNTI United States
- Employees
- GALT N/A
- SNTI N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- SNTI Health Care
- Exchange
- GALT Nasdaq
- SNTI Nasdaq
- Market Cap
- GALT 83.5M
- SNTI 85.3M
- IPO Year
- GALT N/A
- SNTI N/A
- Fundamental
- Price
- GALT $1.31
- SNTI $3.14
- Analyst Decision
- GALT Hold
- SNTI Strong Buy
- Analyst Count
- GALT 1
- SNTI 1
- Target Price
- GALT N/A
- SNTI $12.00
- AVG Volume (30 Days)
- GALT 176.3K
- SNTI 27.9K
- Earning Date
- GALT 05-15-2025
- SNTI 05-06-2025
- Dividend Yield
- GALT N/A
- SNTI N/A
- EPS Growth
- GALT N/A
- SNTI N/A
- EPS
- GALT N/A
- SNTI N/A
- Revenue
- GALT N/A
- SNTI N/A
- Revenue This Year
- GALT N/A
- SNTI N/A
- Revenue Next Year
- GALT N/A
- SNTI N/A
- P/E Ratio
- GALT N/A
- SNTI N/A
- Revenue Growth
- GALT N/A
- SNTI N/A
- 52 Week Low
- GALT $0.73
- SNTI $1.52
- 52 Week High
- GALT $3.17
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- GALT 48.59
- SNTI 44.57
- Support Level
- GALT $1.22
- SNTI $3.03
- Resistance Level
- GALT $1.36
- SNTI $3.50
- Average True Range (ATR)
- GALT 0.10
- SNTI 0.22
- MACD
- GALT -0.00
- SNTI 0.00
- Stochastic Oscillator
- GALT 29.41
- SNTI 23.40
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.